X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4851) 4851
Publication (345) 345
Newsletter (175) 175
Book Review (79) 79
Newspaper Article (22) 22
Transcript (10) 10
Book Chapter (7) 7
Magazine Article (7) 7
Dissertation (6) 6
Trade Publication Article (3) 3
Data Set (2) 2
Paper (2) 2
Web Resource (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3493) 3493
risperidone (3445) 3445
psychiatry (2708) 2708
male (2691) 2691
female (2228) 2228
schizophrenia (2192) 2192
index medicus (1913) 1913
antipsychotic agents - therapeutic use (1892) 1892
antipsychotic agents - administration & dosage (1797) 1797
adult (1780) 1780
pharmacology & pharmacy (1723) 1723
schizophrenia - drug therapy (1687) 1687
antipsychotic agents - adverse effects (1552) 1552
risperidone - administration & dosage (1281) 1281
risperidone - therapeutic use (1242) 1242
middle aged (1223) 1223
olanzapine (1213) 1213
treatment outcome (1121) 1121
risperidone - adverse effects (956) 956
haloperidol (891) 891
double-blind (843) 843
neurosciences (843) 843
adolescent (840) 840
drug therapy (830) 830
antipsychotic drugs (750) 750
clozapine (728) 728
dose-response relationship, drug (722) 722
dosage and administration (708) 708
aged (685) 685
clinical neurology (669) 669
drug administration schedule (637) 637
antipsychotics (598) 598
animals (591) 591
atypical antipsychotics (561) 561
psychotropic drugs (549) 549
psychotic disorders - drug therapy (530) 530
psychiatric status rating scales (528) 528
antipsychotic agents - pharmacology (507) 507
drug therapy, combination (503) 503
double-blind method (496) 496
efficacy (491) 491
drugs (480) 480
research (467) 467
schizophrenic psychology (450) 450
child (434) 434
aripiprazole (419) 419
young adult (415) 415
rats (414) 414
care and treatment (402) 402
risperidone - pharmacology (396) 396
quetiapine (376) 376
time factors (373) 373
benzodiazepines - therapeutic use (365) 365
risk factors (361) 361
neuroleptics (359) 359
mental disorders (349) 349
children (348) 348
delayed-action preparations (341) 341
quetiapine fumarate (326) 326
analysis (310) 310
administration, oral (308) 308
complications and side effects (301) 301
safety (301) 301
psychology, clinical (299) 299
pediatrics (296) 296
bipolar disorder (291) 291
psychosis (285) 285
placebo (282) 282
antipsychotic agents - pharmacokinetics (280) 280
health aspects (279) 279
dopamine (275) 275
retrospective studies (273) 273
paliperidone palmitate (272) 272
schizophrenia - diagnosis (268) 268
benzodiazepines - adverse effects (267) 267
adolescents (266) 266
severity of illness index (264) 264
benzodiazepines - administration & dosage (252) 252
follow-up studies (252) 252
bipolar disorder - drug therapy (249) 249
clinical trials (244) 244
schizoaffective disorder (241) 241
antipsychotic (238) 238
antipsychotic-drugs (235) 235
trial (235) 235
prospective studies (234) 234
pharmacokinetics (226) 226
medicine & public health (219) 219
dibenzothiazepines - therapeutic use (216) 216
aged, 80 and over (213) 213
psychopharmacology (213) 213
risperidone - pharmacokinetics (209) 209
clozapine - therapeutic use (207) 207
haloperidol - administration & dosage (198) 198
benzodiazepines (197) 197
risk (196) 196
patients (190) 190
usage (190) 190
haloperidol - therapeutic use (189) 189
open-label (186) 186
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4942) 4942
French (26) 26
German (25) 25
Japanese (16) 16
Spanish (14) 14
Polish (12) 12
Hungarian (11) 11
Russian (11) 11
Italian (6) 6
Chinese (5) 5
Korean (4) 4
Turkish (3) 3
Portuguese (2) 2
Arabic (1) 1
Czech (1) 1
Danish (1) 1
Finnish (1) 1
Lithuanian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pediatrics, ISSN 0031-4005, 05/2011, Volume 127, Issue 5, pp. e1312 - e1321
CONTEXT: As many as 1 in every 110 children in the United States has an autism spectrum disorder (ASD). Many medical treatments for ASDs have been proposed and... 
Autism spectrum disorders | Antipsychotics | Fluoxetine | Serotonin-reuptake inhibitors | Aripiprazole | Risperidone | Citalopram | Psychostimulants | psychostimulants | MANAGEMENT | HYPERACTIVITY | risperidone | SYMPTOMS | PERVASIVE DEVELOPMENTAL DISORDERS | fluoxetine | serotonin-reuptake inhibitors | COGNITIVE-BEHAVIORAL THERAPY | ADOLESCENTS | antipsychotics | DOUBLE-BLIND | aripiprazole | PEDIATRICS | autism spectrum disorders | RETROSPECTIVE ANALYSIS | citalopram | Piperazines - administration & dosage | Serotonin Antagonists - administration & dosage | Prognosis | Antipsychotic Agents - adverse effects | Humans | Citalopram - adverse effects | Child, Preschool | Male | Child Development Disorders, Pervasive - drug therapy | Dose-Response Relationship, Drug | Quinolones - adverse effects | Serotonin Antagonists - adverse effects | Child Development Disorders, Pervasive - diagnosis | Risperidone - adverse effects | Female | Child | Fluoxetine - adverse effects | Severity of Illness Index | Drug Administration Schedule | Risperidone - administration & dosage | Treatment Outcome | Evidence-Based Medicine | Piperazines - adverse effects | Randomized Controlled Trials as Topic | Antipsychotic Agents - administration & dosage | Quinolones - administration & dosage | Citalopram - administration & dosage | Fluoxetine - administration & dosage | Patient Compliance | Autism | Care and treatment | Dosage and administration | Antipsychotic drugs | Research | Studies | Pediatrics | Systematic review | Medical treatment | Childrens health
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 07/2017, Volume 2017, Issue 7, p. CD009377
Background Haloperidol used alone is recommended to help calm situations of aggression or agitation for people with psychosis. It is widely accessible and may... 
CLINICAL-TRIAL | Humans | Quinolones [administration & dosage] | INTRAMUSCULAR HALOPERIDOL | Aripiprazole | ORAL RISPERIDONE | Antipsychotic Agents [administration & dosage; adverse effects] | Thiazoles [administration & dosage] | MEDICINE, GENERAL & INTERNAL | BLIND DOSE-RESPONSE | Clopenthixol [administration & dosage] | Lorazepam [administration & dosage] | Aggression [drug effects psychology] | Piperazines [administration & dosage] | Haloperidol [administration & dosage; adverse effects] | Psychomotor Agitation [drug therapy] | PARENTERAL HALOPERIDOL | RANDOMIZED-TRIAL | Randomized Controlled Trials as Topic | Sleep | Dystonia [chemically induced] | EMERGENCY TREATMENT | INJECTABLE HALOPERIDOL | RISPERIDONE ORODISPERSIBLE TABLET | RATING-SCALE | Psychotic Disorders [drug therapy psychology] | Dystonia - chemically induced | Tranquilizing Agents - adverse effects | Hypnotics and Sedatives - adverse effects | Antipsychotic Agents - adverse effects | Psychotic Disorders - psychology | Hypnotics and Sedatives - administration & dosage | Haloperidol - administration & dosage | Aggression - psychology | Haloperidol - adverse effects | Psychomotor Agitation - drug therapy | Antipsychotic Agents - administration & dosage | Placebos - therapeutic use | Psychotic Disorders - drug therapy | Aggression - drug effects | Tranquilizing Agents - therapeutic use
Journal Article
Diabetes Technology & Therapeutics, ISSN 1520-9156, 11/2011, Volume 13, Issue 11, pp. 1145 - 1154
Exenatide once-weekly (EQW [2 mg s.c.]) is under development as monotherapy as an adjunct to diet and exercise or as a combination therapy with an oral... 
Reviews | GLYCEMIC CONTROL | EFFICACY | INJECTION | ENDOCRINOLOGY & METABOLISM | SAFETY DATA | BIPOLAR I DISORDER | RANDOMIZED-TRIAL | OPEN-LABEL | RISPERIDONE | EXTENDED-RELEASE | PEPTIDE-1 ANALOG | Glycated Hemoglobin A - analysis | Triazoles - administration & dosage | Triazoles - adverse effects | Humans | Peptides - pharmacokinetics | Polyglycolic Acid - adverse effects | Pyrazines - administration & dosage | Thiazolidinediones - administration & dosage | Peptides - administration & dosage | Capsules | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Venoms - administration & dosage | Adult | Polyglycolic Acid - metabolism | Sitagliptin Phosphate | Lactic Acid - administration & dosage | Polyglycolic Acid - administration & dosage | Hypoglycemic Agents - pharmacokinetics | Venoms - adverse effects | Lactic Acid - metabolism | Thiazolidinediones - adverse effects | Blood Glucose - drug effects | Insulin, Long-Acting - adverse effects | Insulin, Long-Acting - administration & dosage | Insulin Glargine | Pyrazines - adverse effects | Lactic Acid - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Venoms - pharmacokinetics | Type 2 diabetes | Drugs | Drug delivery systems | Forecasts and trends | Drug therapy | Vehicles
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 07/2018, Volume 281, pp. 139 - 177
Journal Article
Journal Article
Journal of Affective Disorders, ISSN 0165-0327, 2013, Volume 152, Issue 1, pp. 12 - 18
Journal Article
ANNALS OF PHARMACOTHERAPY, ISSN 1060-0280, 08/2017, Volume 51, Issue 8, pp. 682 - 695
Objective: To summarize and evaluate the existing literature regarding medications to treat Parkinson's disease (PD) psychosis. Data Sources: MEDLINE (1946 to... 
Parkinson's disease | MANAGEMENT | DOPAMINERGIC-INDUCED HALLUCINATIONS | quetiapine | psychosis | TRIAL | olanzapine | PHARMACOKINETICS | pimavanserin | DOUBLE-BLIND | clozapine | PHARMACOLOGY & PHARMACY | UPDATE | Piperazines - administration & dosage | Clozapine - therapeutic use | Antipsychotic Agents - adverse effects | Clozapine - administration & dosage | Humans | Thiazoles - administration & dosage | Parkinson Disease - drug therapy | Thiazoles - therapeutic use | Thiazoles - adverse effects | Risperidone - therapeutic use | Antipsychotic Agents - therapeutic use | Urea - analogs & derivatives | Risperidone - adverse effects | Urea - administration & dosage | Quetiapine Fumarate - adverse effects | Piperidines - administration & dosage | Psychotic Disorders - psychology | Risperidone - administration & dosage | Piperazines - therapeutic use | Evidence-Based Medicine | Parkinson Disease - psychology | Piperazines - adverse effects | Quetiapine Fumarate - therapeutic use | Randomized Controlled Trials as Topic | Antipsychotic Agents - administration & dosage | Quetiapine Fumarate - administration & dosage | Urea - therapeutic use | Piperidines - therapeutic use | Piperidines - adverse effects | Urea - adverse effects | Benzodiazepines - administration & dosage | Benzodiazepines - adverse effects | Psychotic Disorders - drug therapy | Clozapine - adverse effects | Benzodiazepines - therapeutic use | Practice Guidelines as Topic
Journal Article
Schizophrenia Bulletin, ISSN 0586-7614, 2014, Volume 40, Issue 2, pp. 327 - 340
Some second-generation antipsychotics (SGAs) increase insulin resistance and fat oxidation, but counter intuitively they do not activate lipolysis. This seems... 
olanzapine | glucose | histamine | oxygen consumption | fat oxidation | risperidone | clozapine | body temperature | respiratory exchange ration | IN-VIVO OCCUPANCY | RECEPTOR ANTAGONISTS | PSYCHIATRY | GLUCOSE-TRANSPORT | ACID OXIDATION | ATYPICAL ANTIPSYCHOTICS | SKELETAL-MUSCLE | INSULIN-RESISTANCE | TERM WEIGHT-GAIN | ANIMAL-MODELS | PLASMA-GLUCOSE | Piperazines - administration & dosage | Clozapine - administration & dosage | Motor Activity - drug effects | Male | Quinolones - pharmacology | Aripiprazole | Terfenadine - administration & dosage | Dose-Response Relationship, Drug | Clozapine - pharmacology | Receptors, Histamine H1 - metabolism | Epoxy Compounds - pharmacology | Hypoglycemic Agents - administration & dosage | Time Factors | Astemizole - pharmacology | Epoxy Compounds - administration & dosage | Respiration - drug effects | Behavior, Animal - drug effects | Fatty Acids - metabolism | Terfenadine - pharmacology | Astemizole - administration & dosage | Benzodiazepines - pharmacology | Mice, Inbred C57BL - metabolism | Risperidone - administration & dosage | Risperidone - pharmacology | Piperazines - pharmacology | Hypoglycemic Agents - pharmacology | Antipsychotic Agents - administration & dosage | Quinolones - administration & dosage | Animals | Oxygen Consumption - drug effects | Drug Interactions - physiology | Benzodiazepines - administration & dosage | Mice | Antipsychotic Agents - pharmacology | Energy Metabolism - drug effects | Regular
Journal Article